Financial PerformanceFor 1Q25, the company reported $197,000 in revenue and a net loss of $0.08 per diluted share, compared to an estimate of $335,000 and a net loss of $0.07 per diluted share.
Revenue EstimatesRenovoCath recorded $197K in the first full quarter of commercialization, with orders from more than 10 medical centers not participating in the ongoing Phase 3 TIGeR-PaC study.
Stock ValuationThe company reported a net loss of $0.40 per diluted share for the fourth quarter.